VERA: IgAN: Atacicept phase III ORIGIN3: likely positive but Fabhalta will be hard to hurdle

Ahead of VERA’s upcoming ORGIN3 IgA nephropathy trial in 2Q25, our analysis suggests a positive Phase III outcome that is in line with its IgAN competitors. However, longer-term data from a non-BAFF/APRIL competitive class may be a hurdle...